100% Quality Guarantee
PhD-Level Technical Support
Key Features

Human anti-SARS-CoV2 (S-RBD) (Omicron,BA.5.2) IgG ELISA Kit (AEFI00367)

SKU AEFI00367
Product Type ELISA Kit
Size 96 Assays
Sensitivity 2.34ng/ml
Range 3.9-250ng/ml
ELISA Type Indirect
Reactivity Human
$857

Request a formal quotation

A PDF quote with its own quote number, ready for your purchasing office to raise a PO against. Back within 4 working hours, from a PhD scientist — not an autoresponder.

  • PO-ready PDFQuote number, VAT, Incoterms
  • Volume pricing appliedDiscounts from 2 kits up
  • Valid 30 daysPrices held while you get sign-off
Anything we should know? optional

No account needed. We use your details only to prepare and send this quote. If it's urgent, say so in the box and we'll come back the same working day.

Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

system_update_altDatasheetsystem_update_altMSDS

Human anti-SARS-CoV2 (S-RBD) (Omicron,BA.5.2) IgG ELISA Kit

The Human Anti-SARS-CoV-2 Spike RBD (Omicron BA.5.2) IgG ELISA Kit is specially designed for the accurate detection of IgG antibodies against the SARS-CoV-2 Omicron variant spike receptor-binding domain (RBD) in human serum and plasma samples. This kit offers high sensitivity and specificity, ensuring reliable and reproducible results for research and diagnostic purposes.The Omicron variant has sparked concerns due to its increased transmissibility and potential impact on vaccine efficacy. Detecting IgG antibodies specific to the Omicron variant can provide valuable information on immune response and vaccine effectiveness, aiding in monitoring outbreaks and guiding public health interventions.

This ELISA kit is a valuable tool for researchers and healthcare professionals studying the immune response to the Omicron variant and developing strategies to combat the ongoing COVID-19 pandemic. With its easy-to-use format and high performance, this kit is an essential component in the fight against emerging variants of SARS-CoV-2.

View AllClose

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose